Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 104Fallopian Tube Neoplasms 47Carcinoma, Ovarian Epithelial 27Neoplasms 12Breast Neoplasms 7Neoplasm Metastasis 5Recurrence 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Peritoneal Neoplasms 3Ovarian Cancer Recurrent 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Multiple Myeloma 2Lung Neoplasms 2Disease Progression 2Colorectal Neoplasms 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vaginal Neoplasms 1Vaccinia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sezary Syndrome 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1

Interventions

Bevacizumab 2taxane 1liposomal doxorubicin 1Paclitaxel 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Drug Therapy 1Docetaxel 1Cisplatin 1Biosimilar Pharmaceuticals 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaccinia × liposomal doxorubicin × Gynecologic × Clear all
NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡